This year, a new round of batch procurement, adjustment and negotiation of medical insurance catalogs, tax reduction for rare diseases, encouragement of generic drugs, construction of a unified medical insurance information system, major overhaul of the Drug Management Law, and the "Healthy China Action - Cancer Prevention and Control Implementation Plan (2019-2022)" are all reshaping the pharmaceutical industry landscape from different perspectives, posing more challenges to the transformation and upgrading of enterprises.
Facing the trend of industry restructuring, Cheng Yi Pharmaceutical is committed to using technological innovation as the driving force for sustainable development of enterprises. Since 2019, Cheng Yi Pharmaceutical has increased its research and development efforts, winning the initiative in the game of cost and benefit. The first half of the year saw frequent reports of successful sales of glucosamine hydrochloride series products nationwide. At the beginning of the year, the company received a DMF registration number issued by the US Food and Drug Administration (FDA), laying the foundation for expanding into the North American market. At present, all three specifications of glucosamine hydrochloride capsules have entered the consistency evaluation review of the National Drug Review Center, and are expected to become the first product of this variety in China to pass the consistency evaluation. At the end of September, Cheng Yi Pharmaceutical obtained a national patent for its research on "a preparation method for chlormastine fumarate".
At the same time, Cheng Yi Pharmaceutical has increased its efforts to climb the peak of national level new drug research and development. In March 2018, Cheng Yi Pharmaceutical, together with Ding Jian, academician of the Chinese Academy of Engineering and director of the State Key Laboratory of New Drug Research, created the first "Academician Expert Workstation" in Dongtou, which aims at targeting anti-tumor drugs with a single variety of sales exceeding 1 billion yuan. At the "2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Conference", it was successfully listed on the 2018 China Pharmaceutical Industry Top 100 Series.
When there is an imbalance between the profits and social responsibility of enterprises, the innovation and transformation of pharmaceutical enterprises is the fundamental solution to the contradiction between enterprises. In the future, Cheng Yi Pharmaceutical will focus on marine medicine, biopharmaceuticals, traditional Chinese medicine, and new formulations, while developing the health industry, implementing marketing reforms, and striving to build the company's core competitiveness.